Targeting the epigenome


Session type:

Robert Brown1
1Imperial College London, London, UK


Tumours show widespread aberrant epigenetic changes, leading to changes in expression of genes involved in all the hallmarks of cancer. These epigenetic changes can be reversed, at least temporarily, using small molecule inhibitors of maintenance of the epigenetic state. Some first generation epigenetic therapies are now registered for use in certain haematological malignancies. Our increased understanding of mechanisms controlling the epigenome and its aberrant control in cancer, provide exciting opportunities for novel anticancer approaches. This session will cover some of the emerging epigenetic targets and drug discovery around these targets.